Cohort1: dose level 1
|
Administration route |
intravitreal injection |
Dosage |
2E8 vg |
Pts |
3 |
Age |
Adult, Older_Adult |
References |
PMID:
28526489
|
|
Cohort2: dose level 2
|
Administration route |
intravitreal injection |
Dosage |
2E9 vg |
Pts |
3 |
Age |
Adult, Older_Adult |
References |
PMID:
28526489
|
|
Cohort3: dose level 3
|
Administration route |
intravitreal injection |
Dosage |
6E9 vg |
Pts |
3 |
Age |
Adult, Older_Adult |
Adverse reactions |
3/3(Conjunctival hyperaemia; Eye pain; Eyelids pruritus) |
References |
PMID:
28526489
|
|
Cohort4: dose level 4
|
Administration route |
intravitreal injection |
Dosage |
2E10 vg |
Pts |
10 |
Age |
Adult, Older_Adult |
Outcome |
Five patients had aqueous humour concentrations of sFLT01 that peaked at 32.7-112.0 ng/mL (mean 73.7 ng/mL, SD 30.5) by week 26 with a slight decrease to a mean of 53.2 ng/mL at week 52 (SD 17.1). |
Adverse reactions |
8/10(Conjunctival haemorrhage; Conjunctival oedema; Eye pain; Eyelids pruritus) |
References |
PMID:
28526489
|
|